Literature DB >> 8083692

Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation.

N A Simonian1, B T Hyman.   

Abstract

The activity of cytochrome oxidase (CO), the terminal enzyme of the electron transport chain, has been reported to be decreased in the brains of individuals with Alzheimer's disease (AD). In experimental models, CO activity decreases following functional deafferentation of neural circuits. CO is a holoenzyme composed of 13 nuclear- and mitochondrial-encoded subunits and experimental data indicate that the change in CO activity following deafferented is controlled primarily by regulation of mitochondrial CO gene expression. It has been proposed that the hippocampal formation is deafferented in AD. We therefore hypothesized that an alteration in mitochondrial CO gene expression might underlie the reduction in CO activity in AD. Using in situ hybridization, we found a selective reduction in mRNA levels for a mitochondrial-encoded subunit, CO II, with preservation of mRNA for a nuclear-encoded subunit, CO IV, in the hippocampal formation of individuals with AD. The reduction in CO II mRNA levels was seen both in regions with neurofibrillary tangles, senile plaques, and neuronal loss and regions relatively spared from these neuropathological changes. These data suggest that the reduction in CO activity in brain regions from individuals with AD may be a result of an alteration in mitochondrial CO gene expression that extends beyond neurons directly affected by structural pathology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083692     DOI: 10.1097/00005072-199409000-00010

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  25 in total

1.  The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease.

Authors:  M Y Aksenov; H M Tucker; P Nair; M V Aksenova; D A Butterfield; S Estus; W R Markesbery
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

2.  Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.

Authors:  M C Irizarry; F Soriano; M McNamara; K J Page; D Schenk; D Games; B T Hyman
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

Review 3.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

Review 4.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

Review 5.  Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?

Authors:  P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2012-09-17

Review 6.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 7.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage.

Authors:  Maria Manczak; Byung S Park; Youngsin Jung; P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

9.  Treatment advances in Alzheimer's disease based on the oxidative stress model.

Authors:  Avi L Friedlich; Raj K Rolston; Xiongwei Zhu; Michael W Marlatt; Rudy J Castellani; Akihiko Nunomura; Hyoung-Gon Lee; Gemma Casadesus; George Perry; Mark A Smith
Journal:  F1000 Med Rep       Date:  2009-07-08

Review 10.  Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease.

Authors:  P Hemachandra Reddy
Journal:  Exp Neurol       Date:  2009-04-07       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.